Evidence map›Paper›PMID 34470672›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

Chemoresistance is mediated by ovarian cancer leader cells in vitro.

Nazanin Karimnia, Amy L Wilson, Emma Green, Amelia Matthews, Thomas W Jobling, Magdalena Plebanski, Maree Bilandzic, Andrew N Stephens

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Leader Cells: Invade and Evade-The Frontline of Cancer Progression.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Cancer metabolism and carcinogenesis.Experimental hematology & oncology · 2024
    Review
  6. Review
  7. Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Nazanin Karimnia *Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC, 3168, Australia.
Amy L Wilson *Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC, 3168, Australia.
Emma GreenHudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC, 3168, Australia.
Amelia MatthewsHudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC, 3168, Australia.
Thomas W JoblingMonash Medical Centre, Department of Gynaecology Oncology, Monash Health, Moorabbin, Australia.
Magdalena PlebanskiSchool of Health and Biomedical Sciences, RMIT University, Bundoora, Australia.
Maree Bilandzic *Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC, 3168, Australia. Maree.Bilandzic@hudson.org.au.
Andrew N Stephens *Hudson Institute of Medical Research, 27-31 Wright St, Clayton, VIC, 3168, Australia.
Hudson Institute of Medical Research · AUMonash Medical Centre · AURMIT University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLeader cells are a subset of cancer cells that coordinate the complex cell-cell and cell-matrix interactions required for ovarian cancer migration, invasion, tumour deposition and are negatively associated with progression-free survival and response to therapy. Emerging evidence suggests leader cells may be enriched in response to chemotherapy, underlying disease recurrence following treatment.

methodsCRISPR was used to insert a bicistronic T2A-GFP cassette under the native KRT14 (leader cell) promoter. 2D and 3D drug screens were completed in the presence of chemotherapies used in ovarian cancer management. Leader cell; proliferative (Ki67); and apoptotic status (Cleaved Caspase 3) were defined by live cell imaging and flow cytometry. Quantitative real-time PCR defined "stemness" profiles. Proliferation was assessed on the xCELLigence real time cell analyser. Statistical Analysis was performed using unpaired non-parametric t-tests or one-way ANOVA and Tukey's multiple comparison post hoc.

resultsLeader cells represent a transcriptionally plastic subpopulation of ovarian cancer cells that arise independently of cell division or DNA replication, and exhibit a "stemness" profile that does not correlate with epithelial-to-mesenchymal transition. Chemotherapeutics increased apoptosis-resistant leader cells in vitro, who retained motility and expressed known chemo-resistance markers including ALDH1, Twist and CD44v6. Functional impairment of leader cells restored chemosensitivity, with leader cell-deficient lines failing to recover following chemotherapeutic intervention.

conclusionsOur data demonstrate that ovarian cancer leader cells are resistant to a diverse array of chemotherapeutic agents, and are likely to play a critical role in the recurrence of chemo-resistant disease as drivers of poor treatment outcomes.

Indexed as

Drug Resistance, NeoplasmAntineoplastic AgentsApoptosisCell Line, TumorCell ProliferationCisplatinClustered Regularly Interspaced Short Palindromic RepeatsDNA ReplicationFemaleGreen Fluorescent ProteinsHumansKeratin-14Ovarian NeoplasmsAntineoplastic AgentsCisplatinGreen Fluorescent ProteinsKeratin-14KRT14 protein, humanChemo-resistanceKeratin-14Leader cellsOvarian CancerRecurrence

Identifiers

PMID34470672
PMCPMC8408956
OpenAlexW3198187100

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.